|
Activity Number:
|
50
|
|
Type:
|
Topic Contributed
|
|
Date/Time:
|
Sunday, August 6, 2006 : 4:00 PM to 5:50 PM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #305646 |
|
Title:
|
Issues in the Use of a Composite Endpoint in Megatrials
|
|
Author(s):
|
Steven Snapinn*+
|
|
Companies:
|
Amgen Inc.
|
|
Address:
|
One Amgen Center Drive, Thousand Oaks, CA, 91320,
|
|
Keywords:
|
|
|
Abstract:
|
A megatrial's primary endpoint is often the composite of a number of clinical events. These composite endpoints add complexity to the trial's design and analysis. In this presentation, some of the issues surrounding the use of a composite endpoint---including heterogeneity of the effect of the treatment across components of the endpoint, the appropriate analysis of the components, and considerations for labeling based on a composite endpoint---will be discussed. Several examples of published megatrials will be used.
|
- The address information is for the authors that have a + after their name.
- Authors who are presenting talks have a * after their name.
Back to the full JSM 2006 program |
